3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Prostatic Neoplasms
8
Breast Neoplasms
8
Lung Neoplasms
6
Colorectal Neoplasms
6
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Anatomic Stage I Breast Cancer AJCC v8
4
Rectal Neoplasms
3
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
COVID-19
3
Uterine Cervical Neoplasms
2
Smoking
2
Sarcoma
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Head and Neck Neoplasms
2
Head and Neck Carcinoma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Carcinoma In Situ
2
Xerostomia
1
Urologic Neoplasms
1
Urologic Diseases
1
Interventions
fludarabine
19
Cyclophosphamide
19
fludarabine phosphate
16
Azacitidine
14
Tacrolimus
13
Melphalan
13
venetoclax
10
Cytarabine
10
Busulfan
10
Whole-Body Irradiation
9
Thiotepa
9
Mycophenolic Acid
9
Stem Cell Transplantation
7
Peripheral Blood Stem Cell Transplantation
7
Decitabine
7
decitabine and cedazuridine drug combination
6
Methotrexate
6
Granulocyte Colony-Stimulating Factor
6
Specimen Handling
5
Sirolimus
5
CPX-351
5
AP 1903 reagent
5
thymoglobulin
4
Vorinostat
4
Mesna
4
Injections
4
Daunorubicin
4
Biopsy
4
Ipilimumab
3
Filgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Myelodysplastic Syndromes
×
Standard of Care
×
Clear all
NCT05316701
2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3
Active not recruiting
187 enrolled
15 charts